Analysis
MMI, maker of the Symani surgical robot, raised $125 million in a Series D round led by existing investor BioStar Capital, with new backing from S3 Ventures, Angelini Ventures and an undisclosed strategic corporate investor, according to MedTech Dive. CEO Mark Toland said the company's focus is "translating that adoption into scale."
Symani is designed for soft-tissue open surgery, filtering out a surgeon's hand tremors and translating wrist motion into movements of miniaturized instruments capable of repairing structures as small as lymphatic vessels and nerves -- procedures too delicate for a surgeon's hand alone. The system received FDA de novo classification for microsurgery in 2024 and FDA clearance for soft-tissue dissection in 2025, and holds a CE mark in Europe.
A Small Installed Base, A Big Funding Round
Robotic surgery today is dominated by Intuitive Surgical's da Vinci platform, the category's longtime leader; MMI instead targets the narrower supermicrosurgery niche -- vessels and nerves under a millimeter -- that da Vinci's larger instruments aren't built for. With roughly 50 installed systems and about 3,500 procedures performed since launch, MMI remains a small operator by comparison, and the new capital goes toward expanding access in the U.S. and global markets, generating more clinical evidence, and investing in energy instruments and digital surgery capabilities.
For medtech investors, a $125 million late-stage round in a single-product device company signals confidence that hardware backers have been more cautious about since several surgical-robotics plays struggled to scale past their first FDA indication; BioStar leading rather than merely following suggests existing investors see the installed base, not just the market opportunity, as worth underwriting further.
The company has not disclosed revenue, a valuation for this round, or how much of the $125 million is earmarked for the REMIND trial specifically. An installed base of 50 systems after both an FDA de novo clearance and a 2025 clearance is a modest commercial footprint for a company now on at least its fourth round; whether Symani's adoption curve steepens from here is the number that will decide if this was a scale-up round or a bridge.
The REMIND trial, evaluating whether Symani can help restore drainage pathways in the deep cervical lymph nodes to help clear neurotoxins linked to neurodegenerative disease, had its enrollment expanded to 15 patients this summer after FDA approval -- an early read, not evidence the approach works, but a genuine expansion of what a surgical robot is being asked to do.
